Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$1.49

-0.07 (-4.49%)

09:01
09/30/19
09/30
09:01
09/30/19
09:01

Adaptimmune presents updated data from Phase 1 trial with ADP-A2M4

Adaptimmune Therapeutics presented updated data from patients with synovial sarcoma who were treated in the ongoing Phase 1 trial with SPEAR T-cells targeting MAGE-A4. The oral presentation by Brian Van Tine, MD, PhD of Washington University in St. Louis, occurred earlier today at the European Society for Medical Oncology Congress. This is a Phase 1 dose escalation, multi-tumor trial to assess the safety, tolerability, and antitumor activity of ADP-A2M4 in HLA-A2+ patients. As of Sep. 03, 2019, data from 12 patients with synovial sarcoma treated in the expansion phase of this trial demonstrated a best overall response rate of 58%. There was a disease control rate of 92%, defined as objective overall response and stable disease. Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies. Fatal aplastic anemia was reported in 1 patient with synovial sarcoma in this trial. This event was previously described and reported to the US Food and Drug Administration. The median age of these patients was 54 years and they had received a median of 2 prior lines of systemic therapy. The median dose received was 9.7 billion SPEAR T-cells. Data from patients with synovial sarcoma treated in the expansion phase of this trial were previously reported in May of this year. At that time 8 patients had been assessed, with 6 showing a decrease in tumor size, of which 3 patients had confirmed partial responses and 1 patient had an unconfirmed partial response. Detailed summary of response data presented at ESMO for ADP-A2M4 in patients with synovial sarcoma. Twelve patients received treatment in the expansion phase of this trial and had post-baseline scans to assess efficacy by time of data cutoff: Of the 12 patients with post-baseline scans to assess efficacy: 11/12 showed clinical benefit with best overall responses of PR or stable disease; this represents a disease control rate of 92%; 7/12 had clinical responses representing a best overall response rate of 58% with 5 confirmed PRs by RECIST criteria; 3 of which remain ongoing at the time of data cutoff; 2 of which developed progressive disease and 2 unconfirmed PRs that remain ongoing at the time of data cutoff;Higher peak SPEAR T-cell expansion was associated with decreases in target lesions from baseline.

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

ADAP Adaptimmune
$1.49

-0.07 (-4.49%)

07/29/19
07/29/19
NO CHANGE

Adaptimmune management to meet with Morgan Stanley
Meeting to be held in Boston, MA on July 29 hosted by Morgan Stanley.
08/01/19
GUGG
08/01/19
DOWNGRADE
GUGG
Neutral
Adaptimmune downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy.
08/02/19
GUGG
08/02/19
DOWNGRADE
GUGG
Neutral
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy as he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. Additionally, financing needs may be an overhang, said Schmidt. While results to date for MAGE-A4 in synovial sarcoma "look intriguing," its commercial opportunity is small, added Schmidt.
08/02/19
08/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oshkosh (OSK) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying that while he thinks Oshkosh is a better story than some other machinery names given solid execution and the potential for some growth or at least stability from its non- Access segments, he sees more room for negative catalysts than positive due to the deceleration in macro data, a growing view that AWP will be flat-to-down next year, and order and backlog contraction against a tough comp from FY19. 2. Square (SQ) downgraded to Underperform from Outperform at Evercore ISI. 3. Adaptimmune (ADAP) downgraded to Neutral from Buy at Guggenheim with analyst Michael Schmidt saying he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. 4. Hilton Grand Vacations (HGV) downgraded to Underweight from Neutral at JPMorgan with analyst Brandt Montour saying he expects poor sentiment to weigh on shares until the company's contract sales reaccelerate in a consistent way, which he feels is not likely until 2020. 5. Valaris (VAL) downgraded to Market Perform from Outperform at Wells Fargo with analyst Coleman Sullivan saying he reduced his EBITDA forecasts through 2021 to account for revised rig startup assumptions, more conservative utilization and dayrate assumptions on floaters and revised cost assumptions. Sullivan, who continues to be disappointed by the lack of contracts at rates peers are able to achieve, sees the company's outlook having more inherent risk going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

10:30
11/15/19
11/15
10:30
11/15/19
10:30
On The Fly
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

CS

Credit Suisse

$12.98

0.135 (1.05%)

NVDA

Nvidia

$202.92

-6.96 (-3.32%)

OSTK

Overstock.com

$8.30

0.12 (1.47%)

AMD

AMD

$39.05

0.69 (1.80%)

DPW

DPW Holdings

$1.16

-0.06 (-4.92%)

KODK

Kodak

$2.35

-0.02 (-0.84%)

RIOT

Riot Blockchain

$1.53

-0.05 (-3.16%)

TEUM

Pareteum

$0.39

-0.006 (-1.50%)

SRAX

Social Reality

$1.56

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 09

    Dec

  • 06

    Jan

PPL

PPL Corp.

$33.72

0.1 (0.30%)

10:30
11/15/19
11/15
10:30
11/15/19
10:30
Options
Size call spread in PPL Corp reloads short calls »

Size call spread in PPL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$292.26

2.58 (0.89%)

, HPQ

HP Inc.

$20.13

0.01 (0.05%)

10:29
11/15/19
11/15
10:29
11/15/19
10:29
Recommendations
Netflix, HP Inc., Aramark analyst commentary  »

Gordon Haskett says…

NFLX

Netflix

$292.26

2.58 (0.89%)

HPQ

HP Inc.

$20.13

0.01 (0.05%)

ARMK

Aramark

$43.38

0.08 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 26

    Nov

  • 09

    Dec

  • 10

    Dec

10:25
11/15/19
11/15
10:25
11/15/19
10:25
Conference/Events
Wolfe Research tech strategist to hold analyst/industry webcast »

Tech Strategist…

DTIL

Precision BioSciences

$11.35

-0.45 (-3.81%)

10:25
11/15/19
11/15
10:25
11/15/19
10:25
Conference/Events
Precision BioSciences participates in a conference call with BTIG »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 07

    Dec

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:20
11/15/19
11/15
10:20
11/15/19
10:20
Options
Put sale in VIX appears to exit two-week position for 64% gain »

Put sale in VIX appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
11/15/19
11/15
10:20
11/15/19
10:20
General news
The September business inventory report undershot estimates »

The September business…

AMRN

Amarin

$22.68

1.19 (5.54%)

10:19
11/15/19
11/15
10:19
11/15/19
10:19
On The Fly
One analyst thinks Amarin could rise toward $50 after positive FDA panel vote »

Shares of Amarin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/15/19
11/15
10:17
11/15/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAYS

Paysign

$10.74

-0.53 (-4.70%)

, WAB

Wabtec

$79.36

0.82 (1.04%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PAYS

Paysign

$10.74

-0.53 (-4.70%)

WAB

Wabtec

$79.36

0.82 (1.04%)

AWK

American Water

$117.25

-0.65 (-0.55%)

RIGL

Rigel Pharmaceuticals

$2.32

0.035 (1.53%)

LPSN

LivePerson

$37.54

1.12 (3.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 25

    Nov

  • 26

    Nov

  • 07

    Dec

  • 10

    Dec

MITK

Mitek Systems

$7.35

-0.35 (-4.55%)

, AGCO

Agco

$80.01

-0.11 (-0.14%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MITK

Mitek Systems

$7.35

-0.35 (-4.55%)

AGCO

Agco

$80.01

-0.11 (-0.14%)

GPOR

Gulfport Energy

$2.84

-0.26 (-8.39%)

CNP

CenterPoint Energy

$25.31

-1.37 (-5.13%)

NVDA

Nvidia

$204.18

-5.7 (-2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 13

    Dec

  • 06

    Jan

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$92.55

2.07 (2.29%)

, AMAT

Applied Materials

$61.45

4.56 (8.02%)

10:16
11/15/19
11/15
10:16
11/15/19
10:16
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

QCOM

Qualcomm

$92.55

2.07 (2.29%)

AMAT

Applied Materials

$61.45

4.56 (8.02%)

GRUB

GrubHub

$38.99

0.47 (1.22%)

BCRX

BioCryst

$1.65

0.07 (4.43%)

NVDA

Nvidia

$204.69

-5.19 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 02

    Dec

  • 09

    Dec

  • 09

    Dec

  • 06

    Jan

  • 14

    Nov

AM

Antero Midstream

$5.34

-0.035 (-0.65%)

10:15
11/15/19
11/15
10:15
11/15/19
10:15
Options
Antero Midstream put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
11/15/19
11/15
10:10
11/15/19
10:10
General news
U.S. business inventories were flat in September, with sales slipping -0.2% »

U.S. business inventories…

FBHS

Fortune Brands

$63.32

0.18 (0.29%)

10:09
11/15/19
11/15
10:09
11/15/19
10:09
Downgrade
Fortune Brands rating change  »

Fortune Brands downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$22.66

1.17 (5.44%)

10:05
11/15/19
11/15
10:05
11/15/19
10:05
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

10:05
11/15/19
11/15
10:05
11/15/19
10:05
General news
The industrial production report sharply undershot estimates »

The industrial production…

10:02
11/15/19
11/15
10:02
11/15/19
10:02
General news
Business Inventories data reported »

September Business…

NCNA

NuCana

$5.59

(0.00%)

10:02
11/15/19
11/15
10:02
11/15/19
10:02
Recommendations
NuCana analyst commentary  »

NuCana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KZR

Kezar Life Sciences

$2.59

(0.00%)

10:02
11/15/19
11/15
10:02
11/15/19
10:02
Conference/Events
Kezar Life Sciences management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FSM

Fortuna Silver Mines

$3.01

-0.19 (-5.94%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Fortuna Silver Mines falls -6.3% »

Fortuna Silver Mines is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

LN

Line Corp.

$46.46

-4.13 (-8.16%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Line Corp. falls -8.2% »

Line Corp. is down -8.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CANG

Cango

$5.83

-1.01 (-14.77%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Cango falls -10.4% »

Cango is down -10.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCH

Banco de Chile

$23.88

2.49 (11.64%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Banco de Chile rises 11.5% »

Banco de Chile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.